Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.28 +0.00%

+$0.00 today

Market cap
$571.17M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.23M

Average 0.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$7.37M

FY 2025 · Annual

Investing Cash Flow

-$107,000.00

FY 2025 · Annual

Financing Cash Flow

$13.71M

FY 2025 · Annual

+206.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.19M)(13.07M)(8.89M)(9.54M)(11.44M)
Depreciation & Amortization53K64K56K46K30K
Deferred Income Tax(217K)174K29K14K0
Stock-Based Compensation1.86M2.25M1.69M2.56M2.75M
Change in Working Capital1.41M(1.84M)(195K)112K1.26M
Accounts Receivables72K(63K)246K(126K)126K
Inventory(72K)0000
Accounts Payables74K(149K)66K49K316K
Other Working Capital1.34M(1.62M)(507K)189K815K
Other Non-Cash Items18K(78K)1.69M(5K)32K
Operating Cash Flow(9.06M)(12.5M)(7.31M)(6.82M)(7.37M)
Capital Expenditures(17K)(47K)(17K)(3K)(107K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(55K)000
Investing Cash Flow(17K)(102K)(17K)(3K)(107K)
Debt Repayment00000
Common Stock Issued21.81M13K6.62M3.96M13.71M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.58M0(580K)516K0
Financing Cash Flow25.38M13K6.04M4.48M13.71M
Effect of Forex Changes05K00(10K)
Net Change in Cash16.3M(12.58M)(1.29M)(2.35M)6.23M
Free Cash Flow(9.08M)(12.55M)(7.33M)(6.82M)(7.48M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$11.4M
+ D&A$30.0K
+ Stock-Based Comp$2.8M
+ Deferred Tax$0
+ Working Capital$1.3M
+ Other Non-Cash$32.0K
= Operating Cash Flow-$7.4M
- Capex-$107.0K
= Free Cash Flow-$7.5M

Analysis

FY2025 free cash flow is -$7.5M. FCF conversion is 65.4% of net income. Operating cash flow was -$7.4M, with capex of -$107.0K. The largest bridge item is Stock-Based Comp at $2.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 6, 2026
SC 13GSC 13G filingOct 30, 2026
8-KCurrent reportOct 27, 2026

Does ENTX generate free cash flow?

Entera Bio Ltd. (ENTX) generated -$7.48M of free cash flow in fiscal 2025.

How much operating cash flow does ENTX produce?

Operating cash flow was -$7.37M, before capital expenditures of $107,000.00.